Skip to main content
Premium Trial:

Request an Annual Quote

MBio Achieves ISO 13485:2003 Certification

NEW YORK (GenomeWeb News) – MBio Diagnostics today said that it has achieved ISO 13485:2003 certification for its quality management system.

The certification means that the Boulder, Colo.-based company has demonstrated that it fulfills certain quality system requirements to provide medical devices and related services that consistently meet customer demands. ISO 13485:2003 certification is often the initial step toward obtaining the CE mark in Europe and in countries that honor the mark.

"Achieving this certification is a significant milestone for MBio Diagnostics that brings us closer to the launch of our first product, the MBio CD4 System," MBio CEO Christopher Myatt said in a statement.

The CD4 System is a point-of-care CD4 testing device. CD4 T helper cell destruction is the central immunological feature of HIV infection, MBio said on its website, and CD4 count is crucial in monitoring the progression of HIV. MBio is also developing its MBio Array System, a multiplex fluorescence immunoassay platform for measuring multiple analytes in a single sample.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.